No abstract

Purpose: The goal of this study was to evaluate the clinical effect of propolis gel associated with non surgical therapy in the management of chronic periodontitis. Subjects and Methods: Thirty chronic periodontitis patients were selected in this study with probing depth not less than 5 mm in each site. Patients randomly divided into three groups ten subjects on each. Patients in Group1 were treated with scaling and root planning and local delivery of propolis gel with chitosan polymer. Patients in group 2 were treated with non surgical therapy and propolis gel with polyox polymer. Patients in group 3 were treated with non surgical therapy alone. The clinical parameters were assessed at baseline, 1 month and 3 months. Results: Clinical parameters showed a favorable improvement in group received propolis gel with polyox polymer than the group received propolis gel containing chitosan polymer. Conclusion: Adjunctive use of propolis with polyox polymer to non surgical therapy showed favorable results over use of propolis with chitosan polymer in patients with chronic periodontitis.

Itopride hydrochloride (ITO HCl) is a prokinetic agent, used in the treatment of gastrointestinal motility disorders. The aim of the study was to develop stable mucoadhesive thermoreversible nasal gel to avoid first pass effect. ITO HCl was incorporated into the blends of thermoreversible polymers like poloxamer 407 and various mucoadhesive polymers in different concentrations to increase the contact of the formulations with nasal mucosa. The compatibility between the drug and the suggested polymers was studied by Fourier transform infrared and differential scanning calorimetry (DSC). The formulations were evaluated for clarity, pH, gelation temperature, mucoadhesive strength, gel strength, viscosity, and drug content. In addition, the in vitro drug release and the dissolution efficiency (DE)% were measured. The optimized formulations that showed the highest dissolution efficiency% (DE%) in saline phosphate buffer of pH 6.4 at 35 ± 0.5 °C were chosen for stability testing at temperatures of 4 ± 2 and 25 ± 2 °C/60 ± 5% RH. It was found that F1 and F17 that contain 18% w/v poloxamer 407 and 0.5% w/v of hydroxypropylmethyl cellulose K4M or methyl cellulose (MC), respectively, showed higher stability results as indicated by their higher t values (days).

No abstract

Trifluoperaizne (TFP) is an antipsychotic medication with limited oral bioavailability due to extensive first-pass metabolism; consequently, the goal of this project was to develop Leciplex nanoparticles to improve the bioavailability of TFP and to prolong its nasal residence time for treatment of the depression. Leciplex NPs were prepared using negatively charged phospholipid, cationic surfactant and biocompatible solvent and optimized using the 21 31 full factorial statistical design using various surfactants and different phospholipid to surfactant ratios. Design Expert® software was employed to select the optimum formula. The formulae were characterized regarding their particle size (PS), polydispersity index (PDI), zeta potential (ZP), entrapment efficiency percentages (EE %), amount of drug released after 6 hours (Q6h), transmission electron microscopy analysis, fourier transform infrared ray spectroscopy (FT-IR) and stability for six months. Optimized formula was contained dimethyldidodecylammonium bromide as surfactant and had a